Clinical usefulness of oral immunoglobulins in lung transplant recipients with norovirus gastroenteritis: a case series.
Fiche publication
Date publication
décembre 2014
Journal
Transplantation proceedings
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DORY Anne
Tous les auteurs :
Gairard-Dory AC, Dégot T, Hirschi S, Schuller A, Leclercq A, Renaud-Picard B, Gourieux B, Kessler R
Lien Pubmed
Résumé
Viral gastroenteritis causing diarrhea is a common complication observed in lung transplant recipients. Differently from the mild and typically self-limited disease seen in immunocompetent subjects, immunocompromised patients frequently have a more severe course. Norovirus and rotavirus are among the leading causes of severe gastroenteritis in transplant recipients. Specific treatment is unavailable, although good supportive treatment can significantly reduce morbidity. Previous studies have suggested that oral immunoglobulins may be used for the treatment of acute viral gastroenteritis after solid-organ transplantation. Herein, we conducted a retrospective chart review of 12 lung transplant recipients with norovirus-induced gastroenteritis who were treated with oral immunoglobulins for 2 days. Eleven patients were successfully treated, whereas 1 subject was only mildly improved. Four patients had at least 1 recurrence. No significant adverse effects were observed. We conclude that oral immunoglobulins may be clinically useful for lung transplant recipients with norovirus-induced gastroenteritis.
Mots clés
Administration, Oral, Caliciviridae Infections, drug therapy, Female, Gastroenteritis, drug therapy, Humans, Immunocompromised Host, Immunoglobulins, administration & dosage, Immunologic Factors, administration & dosage, Lung Transplantation, Male, Middle Aged, Norovirus, Pulmonary Disease, Chronic Obstructive, surgery, Retrospective Studies, Transplant Recipients
Référence
Transplant Proc. 2014 12;46(10):3603-5